Healthcare focus Oberland Capital is a healthcare–only private investment firm with over $3 billion AUM, presenting strong cross‑sell opportunities to healthcare technology vendors, contract research organizations, and life sciences service providers seeking strategic financing, royalty monetization, or future product revenue acquisitions.

Flexible financing Their core value proposition includes royalty streams, project‑based financing, and traditional debt/equity investments, signaling openness to structured finance solutions that could pair with portfolio companies needing bespoke funding for launches, clinical programs, or revenue diversification.

Active portfolio moves Recent investments into Verastem and ImmunityBio, plus asset sales from Curis, indicate ongoing deal activity and a willingness to deploy capital across stages and asset types, suggesting timing opportunities for co‑investments, advisory services, or deal flow collaborations.

Growth through partnerships Strategic partnerships, such as Verastem’s tie‑in with IQVIA, highlight the value of data, analytics, and go‑to‑market capabilities; potential sales angles include data/saas enablement, CRO collaboration, and market access solutions for portfolio companies seeking accelerated commercialization.

Scale and reach With multiple hires in quantitative research, business development, and investor relations, Oberland Capital shows a growth trajectory and disciplined analytics culture, offering opportunities to pitch advanced analytics platforms, risk management tools, and investor‑crm services aligned with growth stage investment firms.